Top 50 Health Care Startup Investors in Denmark (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Novo Holdings
VC Fund
|
33 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$130M |
|
BioInnovation Institute
VC Fund
|
19 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Debt Financing | Biotechnology, Medical, Health Care | $516k–$5.2M |
|
Vaekstfonden
VC Fund
|
18 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $440k–$4.6M |
|
Export and Investment Fund
VC Fund
|
16 | Denmark, United States, United Kingdom | Seed, Series A | Software, Biotechnology, Health Care | $390k–$84M |
|
PSV
VC Fund
|
15 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $88k–$4.7M |
|
Seed Capital
VC Fund
|
13 | Denmark, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $515k–$17M |
|
People Ventures
VC Fund
|
7 | Denmark, Sweden, United States | Seed, Pre-Seed, Series A | Software, Health Care, Internet of Things | $1.1M–$21M |
|
Sunstone Life Science Ventures
VC Fund
|
7 | Denmark, Sweden, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
West Hill Capital
VC Fund
|
6 | United Kingdom, Denmark, Germany | Series A, Seed | Software, Health Care, Financial Services | $1.8M–$15M |
|
Gilde Healthcare
VC Fund
|
6 | United States, The Netherlands, Germany | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $8.8M–$120M |
|
Oskare Capital
VC Fund
|
6 | Italy, Denmark, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $1.2M–$5.9M |
|
Antler
VC Fund
|
5 | Singapore, Australia, United Kingdom | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $104k–$29M |
|
Delphinus Venture Capital
VC Fund
|
5 | Denmark | Seed, Venture - Series Unknown, Pre-Seed | Health Care, Food and Beverage, Wellness | $1.7M–$8.1M |
|
RA Capital Management
VC Fund
|
5 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $26M–$235M |
|
VF Venture
VC Fund
|
4 | Denmark, United Kingdom, Iceland | Seed, Series A | Software, SaaS, Biotechnology | $1.2M–$22M |
|
Jesper Brok
Angel
|
4 | Denmark, Ireland | Pre-Seed, Seed, Angel | E-Learning, Recruiting, Communities | $58k–$400k |
|
Innovestor
VC Fund
|
4 | Finland, Denmark, Sweden | Seed, Pre-Seed | Software, Health Care, Information Technology | $163k–$4.5M |
|
HealthCap
VC Fund
|
4 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.7M–$88M |
|
Forbion Capital Partners
VC Fund
|
4 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $15M–$176M |
|
Innovation Fund Denmark
VC Fund
|
4 | Denmark, United States | Grant, Pre-Seed, Seed | Software, Biotechnology, SaaS | $22k–$1.6M |
|
Crowberry Capital
VC Fund
|
3 | Iceland, Denmark, Finland | Seed, Series A, Pre-Seed | Software, Gaming, Health Care | $1k–$17M |
|
DSM Venturing
VC Fund
|
3 | United States, Canada, Israel | Series A, Series B | Biotechnology, Health Care, Manufacturing | $3.5M–$32M |
|
Sofinnova Partners
VC Fund
|
3 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$120M |
|
Ugly Duckling Ventures
VC Fund
|
3 | Denmark, Sweden, Finland | Seed, Pre-Seed | Software, Information Technology, Artificial Intelligence | $876k–$5.5M |
|
Ysios Capital
VC Fund
|
3 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.2M–$135M |
|
Stine Molgaard Sorensen
Angel
|
3 | Denmark | Pre-Seed, Seed | Robotics, Software, Health Care | |
|
Karolinska
VC Fund
|
3 | Sweden, Denmark, United States | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $1.3M–$73M |
|
Bioqube Ventures
VC Fund
|
3 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
Omega Funds
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
byFounders
VC Fund
|
3 | Denmark, United States, Sweden | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Health Care | $800k–$65M |
|
Crista Galli Ventures
VC Fund
|
3 | United Kingdom, United States, Sweden | Seed, Pre-Seed, Series A | Health Care, Medical, Wellness | $655k–$14M |
|
Sagitta Ventures
VC Fund
|
3 | Denmark, Sweden | Series A, Series B | Health Care, Apps, Mobile | $11M–$20M |
|
Sweet Capital
VC Fund
|
3 | United States, United Kingdom, Israel | Seed, Series A | Apps, Software, Mobile | $1.8M–$32M |
|
EIR Ventures
VC Fund
|
3 | Denmark, Sweden, United States | Series A, Seed | Biotechnology, Health Care, Therapeutics | $20M–$73M |
|
Balderton Capital
VC Fund
|
2 | United Kingdom, United States, Germany | Series A, Series B, Series C | Software, Financial Services, Artificial Intelligence | $4.5M–$150M |
|
Lundbeckfonden Ventures
VC Fund
|
2 | United States, Denmark, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | |
|
NOON Ventures
VC Fund
|
2 | Denmark | Seed, Series A | Biotechnology, AgTech, Farming | |
|
CBC Investment Group
VC Fund
|
2 | Sweden, Denmark, Germany | Seed, Series B | Software, Biotechnology, SaaS | |
|
Novo Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Medical | |
|
Alexander Rindom-Andersen
Angel
|
2 | Denmark | Pre-Seed | Mobile, Software, Freelance | $400k–$400k |
|
VentureFriends
VC Fund
|
2 | Greece, United Kingdom, United States | Seed, Series A, Pre-Seed | FinTech, E-Commerce, Software | |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Industrifonden
VC Fund
|
2 | Sweden, United States, Denmark | Series A, Seed | Software, Biotechnology, Information Technology | |
|
Aescap Venture
VC Fund
|
2 | United Kingdom, Austria, Belgium | Series A, Series B | Biotechnology, Pharmaceutical, Chemical | |
|
SR One
VC Fund
|
2 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Johnson & Johnson Development Corporation
VC Fund
|
2 | United States, United Kingdom, Canada | Series C, Series B | Health Care, Biotechnology, Medical | $12M–$49M |
|
Dawn Biopharma
VC Fund
|
2 | Denmark, France, Belgium | Seed, Series A, Series B | Biotechnology, Health Care, Therapeutics | |
|
Inventure
VC Fund
|
2 | Finland, Sweden, United States | Seed, Series A, Series B | Software, Information Technology, Health Care | $549k–$23M |
|
Acorn Venture Fund
VC Fund
|
2 | Denmark | Seed | Health Care | |
| Access all 349 investors in Denmark Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 335
- Round size: Series A $9M–$120M; Series B $12M–$130M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- AlloCure — AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany.The company isdedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.
- PTC Therapeutics — Translating Science. Transforming Lives.
- Freeline — A leading biotechnology company focused on innovative liver directed gene therapies for bleeding disorders and other debilitating, chronic diseases
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Debt Financing
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 73
- Round size: Pre-Seed $516k–$5.2M; Debt Financing $549k–$1.4M; Convertible Note $549k–$1.5M
- Lead/follow: 90% lead, 10% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 196
- Round size: Seed $810k–$4.6M; Pre-Seed $440k–$1.2M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Captego — Unique, high-speed field data capture. Empower your inspectors & surveyors with our unique collection app. Benefit from high quality data to automate reports and data insights.
- LastSwab — LastSwab launched May 2019 through the crowdfunding platform Kickstarter. At $16 a swab, LastSwab is meant to last at least 1,000 uses and is the easy-to-clean, reusable alternative to the abundant waste caused by single-use swabs around the globe. The tip of the swab is made from medical silicone and nylon and comes in a biodegradable case made ofa corn-based material. LastSwab can be easily cleaned using soap and water and is also dishwasher safe. It comes in a standard swab for cleaning and a pointed swab for makeup application. Be the change and #SwabYourHabits.
- Donkey Republic — Donkey Republic is leading bike share service in Europe with footprint in more than 10 key cities in Europe. We operate our locations with partners, and use custom-branded bikes. Our software backbone is developed by us with unique features that ensure we respect public space with our hub-centric service model. At the same time, we maximizepredictability of bike availability and convenience. We pride ourselves in service innovation.
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 119
- Round size: Seed $390k–$11M; Series A $4.7M–$84M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Woba — Woba is a SaaS aiming to support a stress-free work environment and minimise sick leave.
- Embankment — Dedicated to AIFs. Driven by technology, delivered by domain experts
- Landfolk — Landfolk is the new marketplace for the special holiday homes that are hidden around the country. We have hand-picked every single cottage, where there are proud and passionate hosts, who love their holiday homes, but also like to share it with others.
PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 138
- Round size: Seed $500k–$4.7M; Pre-Seed $88k–$2.5M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $42M in 2020
Portfolio highlights
- Viio — Oveo creates cloud-based software that enables any company in any industry to easily discover, manage, optimise and secure all SaaS usage from one platform.We believe employees should be able to enjoy work, be agile, move fast and in turn become more innovative on behalf of the companies they work for. In a subscribed economy a “SaaS-Poweredworkplace” is the enabling foundation to make that vision come true and at Oveo we proud to contribute by making SaaS usage more transparent, manageable and secure. Theircloud-based software enable companies to easily push this transformation and as SaaS adoption continues to skyrocket we will be right here with you - building the platform to manage and optimize the lifecycle of your SaaS applications.
- Woba — Woba is a SaaS aiming to support a stress-free work environment and minimise sick leave.
- Legal Monster — Openli makes privacy transparent. Get control of your data processors and keep your DPAs up to date. Build trust and close deals faster all with Openli.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 186
- Round size: Seed $515k–$5M; Series A $3.5M–$17M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $73M in 2021
Portfolio highlights
- Cardlay — Build your own white-label card and expense management solution with Cardlay. Our platform helps banks, fleets, and tech partners launch modern spend management solutions fast.
- Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
- Odendo — On Odendo you can make a great deal on exciting products while supporting a good cause
Backing founders with people, money and presence | People Ventures
Show more...Investment focus
- Industry: Software, Health Care, Internet of Things
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 34
- Round size: Seed $1.1M–$19M; Pre-Seed $1.5M–$1.6M; Series A $6.3M–$21M
- Lead/follow: 62% lead, 38% follow
Portfolio highlights
- Alrik — Turn your logistics into a competitive advantage and take control of your emissions. We help building material suppliers revolutionize their workflows.
- Klaay — Klaay provides a cloud-based compliance platform focused on automating SOC 2, ISO 27001, GDPR, and related regulatory processes. The company’s software uses AI to support tasks such as evidence collection, risk monitoring, policy management, and audit preparation. Its platform centralizes compliance controls, vendor management, and documentationinto a single system designed to streamline audit readiness. Klaay serves businesses that require structured compliance workflows and ongoing regulatory maintenance through automated and guided processes.
- Passendo — Passendo is the leading email ad server and platform for publishers and advertisers: unlock new revenue with powerful targeting and delivery.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 56
- Round size: Series A $5.5M–$43M; Series B $9.6M–$52M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more...Investment focus
- Industry: Software, Health Care, Financial Services
- Stage:Series A, Seed
- Geography: United Kingdom, Denmark, Germany
Investor stats
- Total investments: 58
- Round size: Seed $2.6M–$5.9M; Series A $1.8M–$15M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Cercare Medical — Cercare Medical designs and develops a software tool for supporting acute stroke management, helping clinicians to evaluate the effect of a stroke. The software draws up the infarct-area within 30 seconds, locate perfusion area from images within 30 seconds and evaluate mismatch and generate a volume number of salvageable tissue. Cercare Medicalwas incorporated in 2013 under the name Combat Stroke and is based in Denmark.
- ATLANT 3D — Micro and nanodevices are built and tested within days instead of months or years.
- Formalize — A Whistleblower Software system made for accountants and lawyers that have clients, the whistleblower software system helps businesses implement a compliant solution that is both secure and transparent. their products are reporting links, case management, partner account they have designed a journey that makes feel safe about the process. AWS ishandling the physical security of the infrastructure, whistleblower software takes the shared responsibility of security between our cloud infrastructure and application seriously.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 127
- Round size: Series A $8.8M–$65M; Series B $15M–$120M; Series C $21M–$75M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $786M in 2023
Portfolio highlights
- Okami Medical — Okami Medical is a medical device company with a mission to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive devices for the occlusion of peripheral vessels.
- ProVerum Medical — The ProVee stent from Proverum Medical uses 3-D geometry which mirrors and engages with the anatomy of the prostate. The system alleviates Lower Urinary Tract Symptoms (LUTS) by opening the prostatic urethra, applying radial force to the prostatic lobes.
- Endovascular Engineering — Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Oskare Capital is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: Italy, Denmark, United Kingdom
Investor stats
- Total investments: 8
- Round size: Seed $1.2M–$3.9M; Series A $4.8M–$5.9M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Singapore, Australia, United Kingdom
Investor stats
- Total investments: 1204
- Round size: Seed $196k–$5.8M; Pre-Seed $104k–$1.1M; Series A $4.6M–$29M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely actively investing — fresh fund, raised $72M in 2024
Portfolio highlights
- Sapyen — We take the fear out of infertility for men. Test for it at home, without stepping out to the hospital and get personalised health recommendations to improve sperm health and increase your chances of conceiving.
- Superflex — Elevate your workflow with Superflex, the ultimate Figma-to-code solution. Our AI instantly converts Figma and Image designs into pixel-perfect, production-ready code that meets your standards and boosts team efficiency.
- One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.
Delphinus Venture Capital is a venture investment management firm.
Show more...Investment focus
- Industry: Health Care, Food and Beverage, Wellness
- Stage:Seed, Venture - Series Unknown, Pre-Seed
- Geography: Denmark
Investor stats
- Total investments: 11
- Round size: Seed $1.7M–$3.4M; Venture - Series Unknown $1.9M–$8.1M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Alcolase — Alcolase is a danish startup who develops the world's first enzyme system breaking down alcohol in the stomach (before it enters the blood).
- Decameal — Decameal envisions future food systems that are stable and sustainable, as well as healthy marine habitats.
- Ardos — Ardos is a developer of radiotherapy software designed to enhance cancer treatment.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 448
- Round size: Series B $26M–$152M; Series C $40M–$200M; Post-IPO Equity $34M–$235M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Seed, Series A
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 29
- Round size: Seed $1.2M–$9.1M; Series A $5.6M–$22M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Tame — ABOUT With Tame you can fully customise your virtual events, and make them fun, engaging & exciting to attend.- Apply your branding: Customise your virtual event completely - Personalised Welcome: Personal welcome message when attendees enter - Multiple stages: Broadcast content across multiple stages. - Live streaming: Stream live via anybroadcasting software - Pre-recorded videos: Broadcast pre-recorded videos as if it was live - Breakout sessions: Enable public or private breakout sessions. - Virtual Sponsor booths: Allow attendees to engage with sponsors live. - Customise Chat: Allow for 1:1 chat, group chat or session chat. - 1:1 Video Meetings: Empower social networking virtually.OUR COMPANY We are an experience-centric company, and we believe in the power of great experiences. Our international group of dreamers, creators and rule-breakers passionate about merging design and technology together, enables us to transform that into one truly amazing event platform.OUR PEOPLE The team behind Tame has an aggregated decades long experience of creating events and building products that solve real problems for real people. So, what got us here? Our ambition to change a broken event industry through innovation, customer obsession and a relentless focus on the great experience.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
Jesper Brok is the Founder of Tjommi and Legalfinder.com.
Show more...Investment focus
- Industry: E-Learning, Recruiting, Communities
- Stage:Pre-Seed, Seed, Angel
- Geography: Denmark, Ireland
Investor stats
- Total investments: 5
- Round size: Pre-Seed $58k–$400k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Healper — An online matching platform where you get matched with the mental health tools and psychologist who fits your personality, demography, and personal factors, giving you the best chance for effective therapy. The platform includes an online survey, psychologist profiles, booking and payment systems, reminders, sessions, and feedback systems. Webelieve better mental health starts with having a therapist in whom you trust, have chemistry with, and have relevant expertise. Healper will make a better match between you and the therapist based on professional and personal factors through a safe and smooth user journey. We believe a better match means better therapy, empowering you to get more out of your life.
- Yard — The community for organisers rebuilding their local tech community
Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Finland, Denmark, Sweden
Investor stats
- Total investments: 79
- Round size: Seed $507k–$4.5M; Pre-Seed $163k–$2M
- Lead/follow: 61% lead, 39% follow
- Last fund: May invest from a new fund soon — raised $35M in 2020
Portfolio highlights
- Innomost — Innomost develops and produces high-value bioactive ingredients from forest industry side streams that enable customers to make innovations in the cosmetic beauty industry. Its current product portfolio consists of birch charcoal powder, birch bark powder, betulin, suberin, and azelaic acid, which can trigger innovation in all cosmetic productcategories including skincare, haircare, body care, decorative cosmetics, and oral care.
- Bahn Express — Bahn Express is a global car transportation company that supports independent contractors while offering quick and easy auto shipping throughout Europe.
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 126
- Round size: Series A $5.7M–$55M; Series B $12M–$88M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $209M in 2019
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 187
- Round size: Series A $16M–$176M; Series B $15M–$155M; Series C $19M–$113M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
- Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 89
- Round size: Seed $66k–$1.3M; Grant $22k–$1.1M; Pre-Seed $64k–$1.6M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Prezio — Prezio is an electricity tariff data API for Europe. We aggregate, structure, and serve real-time and historical electricity pricing data - spot prices, retail tariffs, and grid fees - so energy applications don't have to build and maintain that data infrastructure themselves. Typical customers are developers and product teams building EVsmart charging, heat pump control, home batteries, and solar optimization tools - anything that needs to know what electricity actually costs, right now or over time, across European markets.
- SureShot — SureShot empowers you and your audience to become video co-creators. With our cutting-edge AI, capture, edit, and share electrifying videos that amplify the essence of every event.
- AlterEcho — AlterEcho is redefining aseptic manufacturing by decoupling human operators from cleanroom environments through First-Person View Remote Robotic Embodiment. Instead of direct intervention, operators control precision robotics remotely via first-person-view headsets and motion controllers, maintaining the dexterity and adaptability of humanoversight while eliminating contamination risks. This paradigm shift enables pharmaceutical manufacturers to enhance scalability, optimize facility layouts, and future-proof production against labor shortages and regulatory pressures. Unlike conventional automation, which struggles with edge cases and lengthy validation cycles, AlterEcho keeps human decision-making in the loop while generating the operational data and infrastructure that could enable more autonomous biomanufacturing in the future. A Techstars-backed venture, AlterEcho is not just iterating on aseptic workflows - it’s reengineering the fundamental relationship between humans and pharmaceutical production.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.
Show more...Investment focus
- Industry: Software, Gaming, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Iceland, Denmark, Finland
Investor stats
- Total investments: 48
- Round size: Seed $1.6M–$4.7M; Pre-Seed $1k–$1.3M; Series A $5.7M–$17M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Prescriby — Prescriby is a digital treatment system developer to combat the opioid crisis by improving prescription safety and monitoring.Prescriby features a treatment generator and dashboard monitor to simplify complex health information, allowing clinics to give individualized data-driven therapies and safer monitoring for their customers.
- Dreamdata — Dreamdata is a B2B Revenue Attribution Platform that gathers, joins, cleans all revenue-related data to present transparent, actionable analysis of what drives B2B revenue. The ultimate B2B multi-touch attribution tool for multi-techstack businesses.
- Mainframe Industries — Mainframe Industries is a Reykjavik, Iceland and Helsinki, Finland-based startup working on the development of an open world, social sandbox MMO for cloud gaming.The company will will work on an open-world, social sandbox MMO specifically designed for cloud gaming, with cross-platform play across mobile, PC, and TV. Mainframe believes that thepromise of friction-free access from social networks and streaming platforms on the device of your choice will greatly expand the creative canvas for game developers.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 92
- Round size: Series A $3.5M–$32M; Series B $4.1M–$30M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
- Verdezyne — Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercialfermentation processes for the production of petrochemical replacements.
- NutriLeads — NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 309
- Round size: Series A $6M–$67M; Series B $10M–$120M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Elicit Plant — We work with farmers around the world to meet the challenges of climate change and the impact of water scarcity on field crops.
- l'école — l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.
- EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: Denmark, Sweden, Finland
Investor stats
- Total investments: 18
- Round size: Seed $876k–$5.5M; Pre-Seed $917k–$1.7M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Eupry — Be in full control of your temperature compliance at all times. Collect temperature monitoring, mapping, and calibration in one GxP-compliant solution.
- Unioo — Unioo is a board portal that develops tools and software solutions to revolutionize and manage organizations and volunteer work.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 79
- Round size: Series A $2.2M–$63M; Series B $17M–$135M; Series C $27M–$80M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Cytoki Pharma — Cytoki Pharma is a biotechnology company developing a portfolio of IL-22-based drugs as a new treatment paradigm for serious diseases involving epithelial injury.
Stine Molgaard Sorensen is the Co-founder and COO of Radiobotics.
Show more...Investment focus
- Industry: Robotics, Software, Health Care
- Stage:Pre-Seed, Seed
- Geography: Denmark
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- RiACT — Software for robots. Real-time development platform for creators and users of flexible robot applications.
- NordInsight — Instantly access MRI safety conditions, generate CPT-code ready reports, and standardize your workflow. NordInsight empowers radiology professionals with the tools they need to ensure safe, fast, and compliant MRI scans across all implants.
- Radiobotics — Our flagship product RBfracture is able to detect fractures in X-rays across the entire appendicular skeleton, and is MDR IIa certified. Also available: RBhip, RBknee and RBmarker
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 29
- Round size: Series A $1.3M–$73M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- BOOST Pharma — Boost Pharma: Developing a stem cell therapy for Osteogenesis Imperfecta.
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
- Umecrine Cognition — Umecrine Cognition is a Swedish clinical-stage pharmaceutical company developing a novel class of drugs to treat neurological disorders of the brain.
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$21M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Commit Biologics — Add a description for facebook
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 149
- Round size: Series A $16M–$197M; Series B $35M–$162M; Series C $14M–$208M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
- NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
byFounders is the community-powered early-stage venture fund investing in globally ambitious teams connected to the Nordic and Baltic countries. With its unique Collective of founders and operators, byFounders offers its portfolio operational expertise and a global network. Believing in the power of tech to shape our future, byFounders takes an impact-aware approach to investing and working with the broader startup ecosystem.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, United States, Sweden
Investor stats
- Total investments: 104
- Round size: Seed $1.5M–$8M; Pre-Seed $800k–$4.2M; Series A $6.1M–$65M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely still investing — raised $117M in 2021
Portfolio highlights
- Flare — Flare builds infrastructure for a more internet by connecting real-world data with machine learning in a verifiable way.This combines human intelligence with advanced AI to improve the clarity and reliability of information.Its goal is to create a shared, high-quality knowledge foundation that helps people navigate information with confidence.
- Verda (formerly DataCrunch) — DataCrunch is a cloud service provider which facilitates utilization and integration of state of the art AI/ML models
- Spiral Hydrogen — Spiral Hydrogen's mission is to lower the price of green hydrogen below that of fossil hydrogen, so opening up an industry for decarbonization and making hydrogen transportation and heating commercially viable.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Physician-led venture capital investing in TechBio, DeepTech Healthcare, and Digital Health.
Show more...Investment focus
- Industry: Health Care, Medical, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Sweden
Investor stats
- Total investments: 36
- Round size: Seed $960k–$8.5M; Pre-Seed $655k–$2.5M; Series A $5.2M–$14M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Jude — Science-backed food supplement that makes you feel empowered, not embarrassed.
- Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
- Collective Minds Radiology — Collective Minds develops and delivers a cloud-based collaboration platform for healthcare and research with access to data, human and digital expertise.
Sagitta Ventures invests in early-stage companies in the Nordics and provides long-term capital backing for well-managed businesses that are seeking minority investors without a defined exit horizon.
Show more...Investment focus
- Industry: Health Care, Apps, Mobile
- Stage:Series A, Series B
- Geography: Denmark, Sweden
Investor stats
- Total investments: 5
- Round size: Series A $11M–$20M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Cerebriu — Cerebriu is a health tech company developing machine learning in medical imaging that improves workflow efficiency and quality in radiology.Its software solution Cerebriu Apollo achieves the company's aim by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of thediagnostic process. The company covers findings of the brain, starting with brain MRI, including stroke, bleeds, and tumors, following MS, dementia, and TBI in brain CT.
- Donkey Republic — Donkey Republic is leading bike share service in Europe with footprint in more than 10 key cities in Europe. We operate our locations with partners, and use custom-branded bikes. Our software backbone is developed by us with unique features that ensure we respect public space with our hub-centric service model. At the same time, we maximizepredictability of bike availability and convenience. We pride ourselves in service innovation.
- Heart Aerospace — Heart’s mission is to create the fastest, most affordable and sustainable transportation for regional travel to every corner of the world. Their first aircraft is the ES-19, a nineteen-passenger airliner with an operating range of 400 km. Heart's goal is to have the aircraft certified for commercial operation by 2026.
Sweet Capital is the private investment fund of the founders of King.com (Candy Crush Saga), following their $5.9b sale to Activision Blizzard in 2015 (ATVI:US; acq. MSFT:US).
Show more...Investment focus
- Industry: Apps, Software, Mobile
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 63
- Round size: Seed $1.8M–$5M; Series A $3M–$32M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Pachama — Harnessing AI to drive carbon capture and protect global forests
- Wellthy — Wellthy is a family care concierge service bringing relief to families managing complex or ongoing care situations. The company's solution brings relief to families managing aging-related concerns, childcare, special needs, health conditions, and other complex or ongoing care situations. Wellthy connects families with a dedicated CareCoordinator to help tackle the logistical and administrative tasks of caring for the ones they love, including themselves.Through Wellthy’s online platform, families can keep track of appointments, save contacts, organize tasks by type, store important documents, and revisit past conversations.The company was founded in 2014 by Lindsay Jurist-Rosner and Kevin Roche and is headquartered in New York, United States.
- Immersive Gamebox — Electric Gamebox delivers immersive team Adventures in the world's smartest room. Our GameBox Adventure pods combine projection mapping, touch screen, motion tracking and surround sound technologies to create an entirely new form of digital group entertainment.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 12
- Round size: Series A $20M–$73M
- Lead/follow: 58% lead, 42% follow
- Last fund: Likely still investing — raised $143M in 2021
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- Synklino — Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
- Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more...Investment focus
- Industry: Software, Financial Services, Artificial Intelligence
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 381
- Round size: Series A $4.5M–$30M; Series B $9.3M–$85M; Series C $15M–$150M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely actively investing — fresh fund, raised $615M in 2024
Portfolio highlights
- Clue — Track your menstrual cycle with the Clue app, a women-led period and cycle tracker. Get science-based insights, predictions, and personalized tracking.
- Primer — Primer is the first open automation platform for payments, enabling you to build end-to-end payment flows with no code, and a checkout developers love.
- Quantum Systems — Our vision is to become the global leader in providing aerial data for decision making by the use of our drones.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 65
- Lead/follow: no public data
Portfolio highlights
- ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- Notify Therapeutics — Notify Therapeutics develops therapies for the treatment of infertility. By targeting the early and hormone-independent phase of egg maturation, the company aims at developing a first-in-class treatment for infertile women, who do not benefit from standard hormone therapy. It utilizes drug-inducing factors that regulate the intracellular AKTpathway and target the early and hormone-independent phase of egg maturation for the treatment.
Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Farming
- Stage:Seed, Series A
- Geography: Denmark
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
- Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Series B
- Geography: Sweden, Denmark, Germany
Investor stats
- Total investments: 12
- Lead/follow: no public data
Portfolio highlights
- GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
- Swiftly — World's first AI that applies for jobs. Say goodbye to creating CV's, searching and applying for jobs. Let Swiftly do it for you! Welcome to the new age.
- Hugel Control — HUGEL, Inc. strives to be a global company that continuously creates innovative products, promotes universal health, and improves the quality of life through state-of-the-art technology and creativity.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 78
- Lead/follow: no public data
Portfolio highlights
- PanOptica — PanOptica is a biopharmaceutical company developing a topical eye drop for the treatment of eye diseases caused by abnormal or leaky blood vessels.
- Delenex Therapeutics — Buy the domain name Delenex.com and launch your business with a premium domain and a high quality logo.
- ViewPoint Therapeutics — LogikaQQ adalah situs daftar judi online qq pkv games terpercaya 24 jam game agen dominoqq, bandarqq dan judi qiu qiu poker online terpercaya deposit pulsa.
Alexander Rindom-Andersen is the Co-founder & CEO @ Naetion
Show more...Investment focus
- Industry: Mobile, Software, Freelance
- Stage:Pre-Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Round size: Pre-Seed $400k–$400k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- HJAELP — Marketplace, Digital Workplace, Mobile App
- Naetion — Marketplace, Digital Workplace, Mobile App, Web3
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Backing ambitious early-stage founders across Europe and MENA
Show more...Investment focus
- Industry: FinTech, E-Commerce, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: Greece, United Kingdom, United States
Investor stats
- Total investments: 116
- Lead/follow: no public data
Portfolio highlights
- Huspy — Huspy is a proptech based in Dubai redefining the home financing process through a user friendly digital experience that puts the buyer first.
- Retab — Cube AI boosts back-office logistics efficiency, allowing teams to handle more loads and focus on human relationships.
- Cube AI — Cube AI provides software that applies machine learning to business workflows and data. The platform enables creation of AI assistants, connections to internal data sources, and task automation through APIs and integrations. Capabilities include natural language processing for classification, summarization, and question answering, retrieval overdocuments and knowledge bases, and analytics that surface insights from structured and unstructured data. Solutions cover use cases such as customer support, sales enablement, lead routing, and document processing, helping teams reduce manual steps and standardize processes. Tooling includes SDKs, dashboards, and monitoring to deploy, observe, and refine models in production.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Series A, Seed
- Geography: Sweden, United States, Denmark
Investor stats
- Total investments: 165
- Lead/follow: no public data
Portfolio highlights
- Fibbl — Fibbl is the world's first cost-effective end-to-end solution for 3D and AR focused visual marketing. Integrate 3D & AR into e-commerce and marketing in minutes.Fibbl have industrialized the process of producing photorealistic 3D models for consumer products from global brands. Fibbl has the world's largest 3D model database forconsumer products.Learn more - https://www.fibbl.com/
- Gårdsfisk — Gårdsfisk is a company managing fishing farms. Gårdsfisks develops a new method for fish farming on land. The cultivation takes place in large pools in a closed system, where the nutrient residual water can be reused as fertilizer on the fields.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Chemical
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, Belgium
Investor stats
- Total investments: 13
- Lead/follow: no public data
Portfolio highlights
- Orphazyme — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
- Avantium — Build a sustainable future with Avantium. Leading the change in green chemistry and innovative solutions.
- F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 181
- Lead/follow: no public data
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Spero Therapeutics — Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
- Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 163
- Round size: Seed $2.4M–$21M; Series A $5.2M–$45M; Series B $15M–$100M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- UNISERS — Developing solutions for Universal Contamination Analysis. Working with cutting edge technologies to revolutionize contamination control.
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series C, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 129
- Round size: Series B $15M–$49M; Series C $12M–$40M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Prana Thoracic — A minimally invasive, lung-sparing device that will provide physicians and patients with the certainty they need to move forward with treatment.
- Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
- Osteal Therapeutics — Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
Dawn Biopharma is a global investment firm of KKR.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A, Series B
- Geography: Denmark, France, Belgium
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Bambusa Therapeutics — Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.
Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Finland, Sweden, United States
Investor stats
- Total investments: 165
- Round size: Seed $549k–$6M; Series A $1.3M–$17M; Series B $1.3M–$23M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $169M in 2022
Portfolio highlights
- Finch — Optimize building design with AI and graph technology. Get immediate feedback on performance, detect errors and find optimal solutions.
- Reveel — Say goodbye to paper maps, brochures, and outdated audio guides. Reveel offers digital solutions for destinations such as UNESCO sites, sights, museums, cities, hotels and parks, taking the visitor experience to the next level. Become part of the smart destination movement, enhance the visitor experience, and discover the future of travel.
- ONEiO — ONEiO is a cloud-native integration service provider connecting people, processes, and tools – enabling seamless collaboration without traditional integration hassle. Provided as a turn-key solution, as self-service, or something in between. You choose.
Venture Capital
Show more...Investment focus
- Industry: Health Care
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Healper — An online matching platform where you get matched with the mental health tools and psychologist who fits your personality, demography, and personal factors, giving you the best chance for effective therapy. The platform includes an online survey, psychologist profiles, booking and payment systems, reminders, sessions, and feedback systems. Webelieve better mental health starts with having a therapist in whom you trust, have chemistry with, and have relevant expertise. Healper will make a better match between you and the therapist based on professional and personal factors through a safe and smooth user journey. We believe a better match means better therapy, empowering you to get more out of your life.
Health Care Investor funding in Denmark at a glance
Stats across 415 deals from 349 investors.
Access all 349 investors in Denmark Health Care startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care Investors in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 349 investors investing in Denmark Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!